PHARMA

PHARMA

Pharmaceutical Hydrogenation Membrane in New Zealand

Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. New Zealand's abundant geothermal and wind resources provide low-cost renewable electricity for green hydrogen production.

Market Context

New Zealand

Policy

New Zealand Green Hydrogen Strategy

H₂ Target

Green hydrogen for industrial and transport decarbonization

1

Cities

4

Industries

Ultra-Clean Hydrogen Source

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

GMP-Compatible On-Site Generation

On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.

Batch-Flexible Operation

Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.

Pharmaceutical Hydrogenation in New Zealand’s Hydrogen Market

New Zealand's abundant geothermal and wind resources provide low-cost renewable electricity for green hydrogen production. The country's dairy and agricultural sectors create demand for green ammonia, while heavy transport and remote communities present opportunities for hydrogen fuel.

IONZERA provides New Zealand with a high-performance AWE membrane accessible via the India-Oceania trade corridor, offering competitive pricing and shorter delivery than European alternatives.

Geothermal-to-H2Wind-to-H2Agriculture HydrogenHeavy Transport
3x

Lower Resistance

20%

Thinner Profile

PERFORMANCE ADVANTAGE

Why IONZERA for Pharmaceutical Hydrogenation in New Zealand

Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.

Shipping & Logistics

Air freight from India to Auckland in 6-8 business days.

Area Resistance

3x LOWER
Area Specific Resistance ComparisonIONZERA0.09-0.1 Ω·cm²Zirfon0.30 Ω·cm²00.10.20.3 Ω·cm²~3x Lower

Thickness

20% THINNER
Membrane Thickness ComparisonIONZERA350-410 μmZirfon500 μm500 μm scale20-30%thinnerThinner membrane = More compact stacks= Higher power density

Pharmaceutical Hydrogenation Membrane in New Zealand Cities

Frequently Asked Questions

Why choose IONZERA for pharmaceutical hydrogenation in New Zealand?

IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in New Zealand. IONZERA provides New Zealand with a high-performance AWE membrane accessible via the India-Oceania trade corridor, offering competitive pricing and shorter delivery than European alternatives.

How does IONZERA fit New Zealand's renewable hydrogen approach?

IONZERA's efficient AWE membranes maximize hydrogen output from New Zealand's geothermal and wind resources. Lower membrane resistance means more hydrogen per kWh, improving project economics for NZ's decarbonization goals.

Ready to Start

Request Pharmaceutical Hydrogenation Samples for New Zealand

Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for New Zealand-based projects.

Request Sample